placebo. Perspective from Shannon C. Scott, DO, FACOFP Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes ...

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists ...